Introduction {#s1}
============

Prospective studies of subjects at high risk for type 1 diabetes have demonstrated a period of "dysglycemia" that precedes diagnosis of diabetes by months or years ([@B1],[@B2]). The ability to reliably identify the dysglycemic period and implement early treatment may have important implications for preservation of endogenous insulin secretion and prevention of diabetes complications ([@B3]). The oral glucose tolerance test (OGTT) has a value in predicting progression to diabetes ([@B4]); unfortunately, OGTT results are highly variable during dysglycemia, and repeated OGTTs are poorly accepted by children. HbA~1c~ is easier to measure but, as a single measurement, less sensitive than OGTTs ([@B5]).

In this exploratory study, we analyzed the feasibility and potential utility of continuous glucose monitoring (CGM) in high-risk individuals.

Research Design and Methods {#s2}
===========================

Study Population {#s3}
----------------

Since 1993, the Diabetes Autoimmunity Study in the Young (DAISY) has followed two cohorts of young children at increased risk of type 1 diabetes. The details of screening and follow-up have been previously published ([@B6]). Since October 2011, DAISY subjects with ≥2 positive antibodies (Ab+) were asked to wear a CGM device at their regular study visits every 3--6 months. Fourteen Ab+ children and nine antibody-negative (Ab−) subjects were included in this study, after excluding three Ab− subjects, as they did not have the minimum of 96 h of monitoring. Ab− subjects, either siblings or general population children of DAISY, were matched for age and sex and have never tested positive for islet autoantibodies. Informed consent and assent when applicable were obtained for each study subject. The Colorado Multiple Institutional Review Board approved all study protocols.

CGM {#s4}
---

Subjects were asked to wear a Dexcom SEVEN Plus System ([@B7]) for 5--7 days. Participants were not able to see real-time CGM readings but were given a OneTouch Ultra (LifeScan Inc., Johnson and Johnson, Milpitas, CA) meter for blood glucose calibrations twice per day. For patient safety, the results were reviewed by a study physician at the end of monitoring. This pilot study presents the baseline CGM data, i.e., initial CGM for participants, while longitudinal data collection is currently ongoing.

Statistical Analysis {#s5}
--------------------

Statistical analyses were performed using SAS software version 9.2. The first 12 h of CGM data were removed from the analyses since the accuracy of CGM data is often poor initially. If more than 20% of the data were missing on any given day, the data for that day were also excluded. Measures of glycemic control included HbA~1c~ (DCA2000, Siemens, Bayer Corporation, Elkhart, IN), the overall mean of glucose values, percentage of values above 140 or 200 mg/dL, as well as area under the curve (AUC) of glucose calculated by the trapezoidal rule. Primary variables to characterize glycemic variability included glucose range, the overall SD, and the coefficient of variation (CV). A two-tailed *P* value with an α-level for significance was set at 0.05. We used Wilcoxon--Mann--Whitney tests to compare CGM statistics between groups. We calculated the individual means first and then compared the mean of the individual means between the groups. Additionally, we calculated the AUC of the receiver operating characteristic curve for association with the development of diabetes among Ab+ subjects.

Results {#s6}
=======

The characteristics of study participants (age, sex, ethnicity, BMI z-score) were similar for Ab+ and Ab− subjects, except for slightly increased percentage of missing CGM data in Ab− subjects (13 vs. 9%). The mean age of the subjects was 13.7 years, and the mean HbA~1c~ in the Ab+ subjects was 5.5% (range 3.2--6.3%; 37 \[range 11--45\] mmol/mol). Among the 14 Ab+ subjects, five developed diabetes within 6 months after their CGM visit, and all but one had HbA~1c~ values \<6.5% at diagnosis.

Baseline CGM variables are summarized in [Table 1](#T1){ref-type="table"} for both Ab+ versus Ab− subjects and Ab+ progressors versus Ab+ nonprogressors. The Ab+ subjects showed more impaired glycemia, with percent time spent above 140 mg/dL of 18% compared with 9% in Ab− subjects (*P* = 0.04). The range of sensor values was wider, and the maximum daytime glucose value was higher (221 vs. 168 mg/dL; *P* = 0.011) in Ab+ versus Ab− subjects. Ab+ subjects had increased glycemic variability with both larger SD and larger CV. AUC during daytime was greater in Ab+ subjects. Similarly, the Ab+ progressors showed more impaired glycemia, with percentage of time spent above 140 mg/dL of 31% compared with 12% in Ab+ nonprogressors (*P* = 0.04). Progressors also had larger SD and greater AUC during daytime. Although mean HbA~1c~ was higher among progressors than nonprogressors (5.9 vs. 5.3% \[41 vs. 34 mmol/mol\], respectively), this was not statistically significant (*P* = 0.16). When analyzing only 24 h of CGM data, we found similar results (data not shown). While the results were similar, this study was not powered to formally compare the validity of 24 vs. 96 h.

###### 

CGM measures of glycemic control and variability among Ab+ versus Ab− subjects and among Ab+ progressors versus Ab+ nonprogressors

  Variables                                                                          Ab+ subjects *n* = 14   Ab− subjects *n* = 9   *P* value   Ab+ progressors *n* = 5   Ab+ nonprogressors *n*= 9   *P* value
  ---------------------------------------------------------------------------------- ----------------------- ---------------------- ----------- ------------------------- --------------------------- -----------
  Age, years                                                                         13.8 ± 3.5              13.6 ± 2.0             0.88        11.7 ± 2.3                14.9 ± 3.6                  0.08
  Mean glucose, mg/dL                                                                117 ± 13                109 ± 11               0.07        125 ± 16                  112 ± 8                     0.19
  Mean day[†](#t1n1){ref-type="table-fn"} glucose, mg/dL                             119 ± 13                109 ± 11               0.06        129 ± 15                  114 ± 8                     0.06
  Mean night glucose, mg/dL                                                          111 ± 16                111 ± 15               0.98        115 ± 22                  109 ± 12                    0.52
  Maximum day[†](#t1n1){ref-type="table-fn"} glucose value, mg/dL                    221 ± 53                168 ± 31               0.011       241 ± 38                  210 ± 58                    0.44
  Maximum night glucose value, mg/dL                                                 173 ± 35                170 ± 44               0.57        185 ± 34                  166 ± 36                    0.36
  SD, mg/dL                                                                          26 ± 8                  19 ± 7                 0.039       32 ± 7                    23 ± 7                      0.06
  CV, mg/dL                                                                          22 ± 6                  17 ± 5                 0.046       26 ± 5                    20 ± 6                      0.15
  Range, mg/dL                                                                       166 ± 53                111 ± 43               0.016       182 ± 37                  157 ± 60                    0.3
  \% Time ≥140 mg/dL                                                                 0.18 ± 0.15             0.09 ± 0.09            0.04        0.31 ± 0.18               0.12 ± 0.07                 0.04
  \% Time ≥200 mg/dL                                                                 0.02 ± 0.03             0 ± 0.01               0.075       0.03 ± 0.04               0.01 ± 0.01                 0.06
  AUC,[‡](#t1n2){ref-type="table-fn"} mg/min/dL                                      676,196 ± 72,197        627,443 ± 64,823       0.16        725,629 ± 91,052          648,733 ± 44,149            0.15
  AUC[‡](#t1n2){ref-type="table-fn"} day,[†](#t1n1){ref-type="table-fn"} mg/min/dL   514,433 ± 54,758        466,436 ± 48,577       0.06        561,040 ± 61,792          488,540 ± 29,180            0.02
  AUC[‡](#t1n2){ref-type="table-fn"} night, mg/min/dL                                160,977 ± 22,912        158,913 ± 22,308       0.60        164,180 ± 32,128          159,198 ± 18,082            0.52
  HbA~1c~, % (mmol/mol)                                                              5.5 ± 0.8 (37 ± 8.7)    NA                     NA          5.9 ± 0.3 (41 ± 3.3)      5.3 ± 0.9 (34 ± 9.8)        0.16

Values are mean ± SD. NA, HbA~1c~ not done in Ab− subjects.

†Day values are between 6:00 [a.m.]{.smallcaps} and midnight.

‡AUC calculated by the trapezoidal rule.

Among Ab+ subjects, the AUC of the receiver operating characteristic curve for association with the development of diabetes was 0.84 (95% CI 0.60--1.00). For 18% of the time spent above 140 mg/dL, the sensitivity was 80%, with a specificity of 78%, while for 20% of the time spent above 140 mg/dL, the sensitivity was 60%, with a specificity of 89%.

[Supplementary Fig. 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc13-2965/-/DC1) describes the evolution of the CGM pattern with available HbA~1c~ and OGTT results for one of the Ab+ subjects who progressed to diabetes.

Conclusions {#s7}
===========

To our knowledge, this is the first study to perform CGM in a group of subjects at high risk of developing type 1 diabetes. Children with ≥2 Ab+ have a 70% risk for developing diabetes in 10 years following appearance of autoantibodies ([@B8]); however, the individual course is highly unpredictable.

Despite nondiabetic HbA~1c~, the Ab+ subjects had significantly increased glycemic variability and spent more time with glucose above 140 mg/dL than Ab− subjects. The percentage of time above 140 mg/dL in Ab− subjects (9%) was higher than previously reported in 74 healthy, nondiabetic individuals (0.4%) ([@B9]), likely due to the fact that these DAISY subjects are at increased genetic risk for diabetes.

We have previously reported that DAISY participants with persistent islet autoimmunity experience steadily increasing HbA~1c~, within the normal range, during several years preceding diabetes ([@B2]). On the other hand, a combined analysis of 1,982 high-risk subjects younger than 21 years of age found that a single value of HbA~1c~ \>6.5% was highly specific for diabetes, but the sensitivity to detect impaired glucose tolerance was rather low across the studies (8--42%) ([@B5]). In this context, the CGM approach shows potential promise as a minimally invasive and nearly instantaneous way to identify subjects with mild hyperglycemia and diagnose diabetes.

Although our numbers are small, the percentage of time spent \>140 mg/dL seems to be predictive of diabetes. The proposed threshold could possibly be modified by age and other factors. The higher prediction of the AUC glucose during the day than the AUC glucose during the night suggests that postprandial glucose levels are predictive. However, this pilot study is too small to determine which CGM variable would be best in predicting development of type 1 diabetes. Further prospective data may help with earlier diagnosis of diabetes and/or more accurate staging of diabetes since intermediate end points will be useful in the future design of type 1 diabetes prevention clinical trials ([@B10]).

Mild hyperglycemia can be detected by CGM and may help with earlier diagnosis of diabetes. Confirmation in larger prospective studies is needed to define CGM criteria useful for type 1 diabetes prediction and diagnosis.

This article contains Supplementary Data online at <http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc13-2965/-/DC1>.
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